DREAM Multiple Sclerosis Trial at EvergreenHealth


Are you living with MS?

Do you also have insomnia and fatigue?

If so, you could qualify for the “DREAM” study, investigating the safety and efficacy of a medication for treating insomnia in people with multiple sclerosis and fatigue.


The EvergreenHealth Multiple Sclerosis Center is conducting a randomized, double-blind, placebo controlled, cross-over trial to assess the safety, tolerability and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue.

DREAM - A Double-blind, CrossoveR, placebo-controlled Study to compare the Effects of Nighttime Administration of suvorexant in Patients with Multiple Sclerosis fatigue and insomnia.


Am I eligible to participate?
Patients 18-75 years of age with a confirmed diagnosis of Multiple Sclerosis and Insomnia Disorder.

Patients must be on a stable regimen of disease modifying therapy with no MS exacerbations for 60 days prior to screening.

Other inclusion and exclusion criteria may apply—we welcome you to contact our research team to learn if participating in this trial is right for you.


What does participation involve?
This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS.

Eligible patients will be asked to wear a FitBit™ device which will be provided by EvergreenHealth.

Enrolled patients will come to the study site for four visits (45 – 90 minutes each) during the study.

Patients will also have 3 or more phone conversations with a study coordinator.


Trial Investigator: Theodore Brown, MD, MPH

For More Information: contact the EvergreenHealth Research Department hotline at 425.899.5385 and ask about the DREAM study.


If you’re interested in enrolling, please submit this brief form, and a member of our research team will contact you.

You’re also welcome to contact the research team directly at 425.899.5385 or EvergreenResearch@evergreenhealth.com.  We look forward to discussing your participation and answering your questions.